AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the...
Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL
BOSTON, March 5, 2025 /PRNewswire/ -- Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stage biotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has...
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1], [2] The FDA approval is based on robust clinical evidence, which show...
Lichen China Limited Announces Effective Date of Reverse Stock Split and Name Change
XIAMEN, China, Feb. 27, 2025 /PRNewswire/ -- Lichen China Limited (Nasdaq: LICN) ("Lichen China" or the "Company"), a dedicated financial and taxation service provider in China today announced the date of effectiveness and the ratio of a forthcoming...
So-Young Receives Approval to Transfer to Nasdaq Capital Market and Extension of Minimum Bid Price Compliance Period
BEIJING, Feb. 27, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics...
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) HONG KONG, Feb. 27, 2025 /PRNewswire/ -- The...
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary,...
Invesco QQQ ETF approved for sale, cross-lists on Hong Kong Stock Exchange
First cross-listing of Invesco QQQ outside of North America; QQQ is the second most traded US ETF Important Information The Trust seeks to track the investment results, before fees and expenses, of the Nasdaq-100 Index® ("Index"). Investors should...
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain...
VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic
SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ -- On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (active ingredient: Opiranserin HCl), has received approval from the...